The Potential Role of Cytokines and Growth Factors in the Pathogenesis of Alzheimer’s Disease
暂无分享,去创建一个
P. Reddy | R. Kandimalla | U. Anand | V. De Feo | K. Gill | Parul Goel | S. Dewanjee | Pratik Chakraborty | Jayalakshmi Vallamkondu | A. Chaudhary | V. Kolli | Chandrasekhar Valupadas | Gilbert Ogunmokun | Hari Prasad Reddy Paluru
[1] P. Reddy,et al. Emerging COVID-19 Neurological Manifestations: Present Outlook and Potential Neurological Challenges in COVID-19 Pandemic , 2021, Molecular Neurobiology.
[2] Vishal C. Kalel,et al. COVID-19, Neuropathology, and Aging: SARS-CoV-2 Neurological Infection, Mechanism, and Associated Complications , 2021, Frontiers in Aging Neuroscience.
[3] P. Reddy,et al. The Emerging Role of HDACs: Pathology and Therapeutic Targets in Diabetes Mellitus , 2021, Cells.
[4] S. Rivest,et al. Targeting innate immunity to protect and cure Alzheimer’s disease: opportunities and pitfalls , 2021, Molecular Psychiatry.
[5] P. Reddy,et al. Autophagy in the diabetic heart: A potential pharmacotherapeutic target in diabetic cardiomyopathy , 2021, Ageing Research Reviews.
[6] B. Casali,et al. Microglial Function and Regulation during Development, Homeostasis and Alzheimer’s Disease , 2021, Cells.
[7] C. Norris,et al. Reactive astrocytes: The nexus of pathological and clinical hallmarks of Alzheimer’s disease , 2021, Ageing Research Reviews.
[8] A. Moin,et al. Modulating neuroinflammation in neurodegeneration-related dementia: can microglial toll-like receptors pull the plug? , 2021, Metabolic Brain Disease.
[9] J. Włodarczyk,et al. Cellular Senescence in Brain Aging , 2021, Frontiers in Aging Neuroscience.
[10] T. Theoharides,et al. Neuroinflammation in Alzheimer's disease and beneficial action of luteolin , 2021, BioFactors.
[11] T. Yamashita,et al. Complement cascade functions during brain development and neurodegeneration , 2021, The FEBS journal.
[12] J. Sabbatinelli,et al. Connecting vascular aging and frailty in Alzheimer’s disease , 2021, Mechanisms of Ageing and Development.
[13] R. Kandimalla,et al. Mitochondrial dysfunction, mitophagy, and role of dynamin‐related protein 1 in Alzheimer's disease , 2021, Journal of neuroscience research.
[14] Puneet Kumar,et al. Neuroprotection through G-CSF: recent advances and future viewpoints , 2021, Pharmacological Reports.
[15] V. Andrisano,et al. Glycogen Synthase Kinase 3β: A New Gold Rush in Anti-Alzheimer’s Disease Multitarget Drug Discovery? , 2020, Journal of medicinal chemistry.
[16] Song Li,et al. New therapeutics beyond amyloid-β and tau for the treatment of Alzheimer’s disease , 2020, Acta Pharmacologica Sinica.
[17] R. Morishita,et al. Insight into the Role of Angiopoietins in Ageing-Associated Diseases , 2020, Cells.
[18] G. Šimić,et al. The Association between TNF-alpha, IL-1 alpha and IL-10 with Alzheimer's Disease. , 2020, Current Alzheimer research.
[19] M. Noroozian,et al. Do serum GDNF levels correlate with severity of Alzheimer’s disease? , 2020, Neurological Sciences.
[20] S. Kaul,et al. Identification of Caffeic Acid Phenethyl Ester (CAPE) as a Potent Neurodifferentiating Natural Compound That Improves Cognitive and Physiological Functions in Animal Models of Neurodegenerative Diseases , 2020, Frontiers in Aging Neuroscience.
[21] H. Braak,et al. Hypothesis: Tau pathology is an initiating factor in sporadic Alzheimer's disease , 2020, Alzheimer's & dementia : the journal of the Alzheimer's Association.
[22] E. Khedr,et al. Cognitive Impairment, P300, and Transforming Growth Factor β1 in Different Forms of Dementia. , 2020, Journal of Alzheimer's disease : JAD.
[23] C. Geula,et al. Accumulation of neurofibrillary tangles and activated microglia is associated with lower neuron densities in the aphasic variant of Alzheimer’s disease , 2020, Brain pathology.
[24] G. Corso,et al. Blood biomarkers indicate that the preclinical stages of Alzheimer's disease present overlapping molecular features , 2020, Scientific Reports.
[25] E. Tai,et al. Shared signaling pathways in Alzheimer’s and metabolic disease may point to new treatment approaches , 2020, The FEBS journal.
[26] X-F Li,et al. Progress in the study of markers related to glioma prognosis. , 2020, European review for medical and pharmacological sciences.
[27] J. Lukens,et al. The role of innate immunity in Alzheimer's disease , 2020, Immunological reviews.
[28] Yitao Wang,et al. NRBF2 is a RAB7 effector required for autophagosome maturation and mediates the association of APP-CTFs with active form of RAB7 for degradation , 2020, Autophagy.
[29] T. Behl,et al. Multifarious roles of mTOR signaling in cognitive aging and cerebrovascular dysfunction of Alzheimer's disease. , 2020, IUBMB life.
[30] D. Morgan,et al. CCL2 Overexpression in the Brain Promotes Glial Activation and Accelerates Tau Pathology in a Mouse Model of Tauopathy , 2020, Frontiers in Immunology.
[31] B. Rossi,et al. In vitro Models of Neurodegenerative Diseases , 2020, Frontiers in Cell and Developmental Biology.
[32] B. Winblad,et al. Quantifying and Describing the Natural History and Costs of Alzheimer’s Disease and Effects of Hypothetical Interventions , 2020, Journal of Alzheimer's disease : JAD.
[33] N. Toschi,et al. A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer's Disease , 2020, Frontiers in Immunology.
[34] A. Giovino,et al. Advanced Glycation End Products (AGEs): Biochemistry, Signaling, Analytical Methods, and Epigenetic Effects , 2020, Oxidative medicine and cellular longevity.
[35] S. Di Nuovo,et al. The cytokine network in the pathogenesis of major depressive disorder. Close to translation? , 2020, Autoimmunity reviews.
[36] Zhi-Yong Xiao,et al. Angiopoietin-1 accelerates Alzheimer's disease via FOXA2/PEN2/APP pathway in APP/PS1 mice. , 2020, Life sciences.
[37] A. Tong,et al. The role of astrocytes in oxidative stress of central nervous system: A mixed blessing , 2020, Cell proliferation.
[38] A. Tenner. Complement-Mediated Events in Alzheimer’s Disease: Mechanisms and Potential Therapeutic Targets , 2020, The Journal of Immunology.
[39] Nicholas E. Propson,et al. Type I interferon response drives neuroinflammation and synapse loss in Alzheimer disease. , 2020, The Journal of clinical investigation.
[40] Michael R. Elliott,et al. IL-1β-driven amyloid plaque clearance is associated with an expansion of transcriptionally reprogrammed microglia , 2019, Journal of Neuroinflammation.
[41] X. Yao,et al. Neurotrophin receptor p75 mediates amyloid β-induced tau pathology , 2019, Neurobiology of Disease.
[42] M. Hamblin,et al. Neural stem cell therapy for neurovascular injury in Alzheimer's disease , 2019, Experimental Neurology.
[43] M. Sabbagh,et al. The path forward in Alzheimer's disease therapeutics: Reevaluating the amyloid cascade hypothesis , 2019, Alzheimer's & Dementia.
[44] Yuquan Wei,et al. Epigenetic regulation of macrophages: from homeostasis maintenance to host defense , 2019, Cellular & Molecular Immunology.
[45] K. Iverfeldt,et al. Phosphorylation of the amyloid precursor protein (APP) at Ser-675 promotes APP processing involving meprin β , 2019, The Journal of Biological Chemistry.
[46] M. Gurney,et al. Tumor Necrosis Factor (TNF) Blocking Agents are Associated with Lower Risk for Alzheimer’s Disease in Patients with Rheumatoid Arthritis and Psoriasis , 2019 .
[47] Sung Hoon Baik,et al. Mimicry of Central-Peripheral Immunity in Alzheimer's Disease and Discovery of Neurodegenerative Roles in Neutrophil , 2019, Front. Immunol..
[48] J. Plemel,et al. Central Nervous System Remyelination: Roles of Glia and Innate Immune Cells , 2019, Front. Mol. Neurosci..
[49] K. Nie,et al. Macrophage Migration Inhibitory Factor Mediates Neuroprotective Effects by Regulating Inflammation, Apoptosis and Autophagy in Parkinson's Disease , 2019, Neuroscience.
[50] M. Wolf,et al. FGF23 at the crossroads of phosphate, iron economy and erythropoiesis , 2019, Nature Reviews Nephrology.
[51] L. Khorsandi,et al. The effect of triiodothyronine on the hippocampal long-term potentiation in an animal model of the Alzheimer's disease: The role of BDNF and reelin , 2019, Neurology, Psychiatry and Brain Research.
[52] A. Cuello. Editorial: The Involvement of NGF in the Alzheimer's Pathology , 2019, Front. Neurosci..
[53] R. Biringer. The Role of Eicosanoids in Alzheimer’s Disease , 2019, International journal of environmental research and public health.
[54] A. Israelson,et al. AAV2/9-mediated overexpression of MIF inhibits SOD1 misfolding, delays disease onset, and extends survival in mouse models of ALS , 2019, Proceedings of the National Academy of Sciences.
[55] C. Matute,et al. Aβ oligomers promote oligodendrocyte differentiation and maturation via integrin β1 and Fyn kinase signaling , 2019, Cell Death & Disease.
[56] M. Naveed,et al. Cerebrovascular inflammation: A critical trigger for neurovascular injury? , 2019, Neurochemistry International.
[57] A. Kuhad,et al. Quinolinic Acid and Nuclear Factor Erythroid 2-Related Factor 2 in Depression: Role in Neuroprogression , 2019, Front. Pharmacol..
[58] K. Prasad. AGE–RAGE stress: a changing landscape in pathology and treatment of Alzheimer’s disease , 2019, Molecular and Cellular Biochemistry.
[59] R. Faull,et al. Vascular Dysfunction in Alzheimer’s Disease: A Prelude to the Pathological Process or a Consequence of It? , 2019, Journal of clinical medicine.
[60] J. Palha,et al. Proinflammatory and anti-inflammatory cytokines in the CSF of patients with Alzheimer's disease and their correlation with cognitive decline , 2019, Neurobiology of Aging.
[61] D. Michaelson,et al. ApoE4: an emerging therapeutic target for Alzheimer’s disease , 2019, BMC Medicine.
[62] V. Sharma,et al. Activation of microglia and astrocytes: a roadway to neuroinflammation and Alzheimer’s disease , 2019, Inflammopharmacology.
[63] R. Yan,et al. A Close Look at BACE1 Inhibitors for Alzheimer’s Disease Treatment , 2019, CNS Drugs.
[64] M. Eriksdotter,et al. Innovative Therapy for Alzheimer’s Disease-With Focus on Biodelivery of NGF , 2019, Front. Neurosci..
[65] Xiangdong Gao,et al. Fibroblast growth factor 21 ameliorates neurodegeneration in rat and cellular models of Alzheimer’s disease , 2019, Redox biology.
[66] B. Vincent,et al. Multidisciplinary approaches for targeting the secretase protein family as a therapeutic route for Alzheimer's disease , 2019, Medicinal research reviews.
[67] M. Alshammari,et al. Neuroinflammatory Cytokines Induce Amyloid Beta Neurotoxicity through Modulating Amyloid Precursor Protein Levels/Metabolism , 2018, BioMed research international.
[68] A. Alonso,et al. Hyperphosphorylation of Tau Associates With Changes in Its Function Beyond Microtubule Stability , 2018, Front. Cell. Neurosci..
[69] L. Estrada,et al. Transforming Growth Factor Beta Type I Role in Neurodegeneration: Implications for Alzheimer´s Disease. , 2018, Current protein & peptide science.
[70] E. Newcombe,et al. Inflammation: the link between comorbidities, genetics, and Alzheimer’s disease , 2018, Journal of Neuroinflammation.
[71] B. Lamb,et al. Inflammation as a central mechanism in Alzheimer's disease , 2018, Alzheimer's & dementia.
[72] L. Tan,et al. Innate immune activation in Alzheimer's disease. , 2018, Annals of translational medicine.
[73] Xu Wang,et al. Emerging Roles of Astrocytes in Neuro-Vascular Unit and the Tripartite Synapse With Emphasis on Reactive Gliosis in the Context of Alzheimer’s Disease , 2018, Front. Cell. Neurosci..
[74] Xiaoyan Qin,et al. Postmortem Brain, Cerebrospinal Fluid, and Blood Neurotrophic Factor Levels in Alzheimer’s Disease: A Systematic Review and Meta-Analysis , 2018, Journal of Molecular Neuroscience.
[75] J. Kamińska,et al. CXCL9, CXCL10, CXCL11, and their receptor (CXCR3) in neuroinflammation and neurodegeneration. , 2018, Advances in clinical and experimental medicine : official organ Wroclaw Medical University.
[76] M. Awais,et al. IP-10 Promotes Blood–Brain Barrier Damage by Inducing Tumor Necrosis Factor Alpha Production in Japanese Encephalitis , 2018, Front. Immunol..
[77] Shu-Qun Liu,et al. Suppression of MIF-induced neuronal apoptosis may underlie the therapeutic effects of effective components of Fufang Danshen in the treatment of Alzheimer's disease , 2018, Acta Pharmacologica Sinica.
[78] P. Reddy,et al. Hippocampal mutant APP and amyloid beta-induced cognitive decline, dendritic spine loss, defective autophagy, mitophagy and mitochondrial abnormalities in a mouse model of Alzheimer’s disease , 2018, Human molecular genetics.
[79] A. Tolkovsky,et al. Neuronal Cell Death. , 2018, Physiological reviews.
[80] Francesc X. Soriano,et al. Excitotoxicity in the pathogenesis of neurological and psychiatric disorders: Therapeutic implications , 2018, Journal of psychopharmacology.
[81] P. Lewczuk,et al. Amyloid β oligomers (AβOs) in Alzheimer’s disease , 2018, Journal of Neural Transmission.
[82] A. Atanasov,et al. Autophagy and Alzheimer’s Disease: From Molecular Mechanisms to Therapeutic Implications , 2018, Front. Aging Neurosci..
[83] M. Fukaya,et al. Dysfunctional autophagy following exposure to pro-inflammatory cytokines contributes to pancreatic β-cell apoptosis , 2018, Cell Death & Disease.
[84] L. Du,et al. Role of Microglia in Neurological Disorders and Their Potentials as a Therapeutic Target , 2017, Molecular Neurobiology.
[85] T. Numakawa,et al. Actions of Brain-Derived Neurotrophic Factor and Glucocorticoid Stress in Neurogenesis , 2017, International journal of molecular sciences.
[86] M. Tomás,et al. Oxidative stress and the amyloid beta peptide in Alzheimer’s disease , 2017, Redox biology.
[87] S. Kaul,et al. 2,3-Dihydro-3β-methoxy Withaferin-A Protects Normal Cells against Stress: Molecular Evidence of Its Potent Cytoprotective Activity. , 2017, Journal of natural products.
[88] M. Mesulam,et al. WITHDRAWN: Revisiting the cholinergic hypothesis in Alzheimer's disease: Emerging evidence from translational and clinical research. , 2017, Alzheimer's & dementia : the journal of the Alzheimer's Association.
[89] Z. Yue,et al. NRBF2 is involved in the autophagic degradation process of APP-CTFs in Alzheimer disease models , 2017, Autophagy.
[90] S. Tsai. Effects of interleukin-1beta polymorphisms on brain function and behavior in healthy and psychiatric disease conditions. , 2017, Cytokine & growth factor reviews.
[91] K. Gomes,et al. Alzheimer’s disease and cytokine IL-10 gene polymorphisms: is there an association? , 2017, Arquivos de Neuro-Psiquiatria.
[92] Jahan B. Ghasemi,et al. In Silico Studies in Drug Research Against Neurodegenerative Diseases , 2017, Current neuropharmacology.
[93] Winnie S. Liang,et al. Necroptosis activation in Alzheimer's disease , 2017, Nature Neuroscience.
[94] J. Little,et al. High Glucose Enhances Neurotoxicity and Inflammatory Cytokine Secretion by Stimulated Human Astrocytes. , 2017, Current Alzheimer research.
[95] A. Ramírez,et al. [Search for risk genes in Alzheimer's disease]. , 2017, Der Nervenarzt.
[96] J. Wojcik,et al. Markers of neuroinflammation associated with Alzheimer’s disease pathology in older adults , 2017, Brain, Behavior, and Immunity.
[97] J. Ojala,et al. The Role of Interleukin-18, Oxidative Stress and Metabolic Syndrome in Alzheimer’s Disease , 2017, Journal of clinical medicine.
[98] Eugenia Trushina,et al. Oxidative Stress, Synaptic Dysfunction, and Alzheimer’s Disease , 2017, Journal of Alzheimer's disease : JAD.
[99] A. Çeti̇n,et al. SDF-1/CXCL12 and CXCR4 gene variants, and elevated serum SDF-1 levels are associated with preeclampsia , 2017, Hypertension in pregnancy.
[100] I. Martin. Resveratrol for Alzheimer’s disease? , 2017, Science Translational Medicine.
[101] Debomoy K Lahiri,et al. Targeting Tumor Necrosis Factor Alpha for Alzheimer's Disease. , 2016, Current Alzheimer research.
[102] R. Bucala,et al. Endogenous macrophage migration inhibitory factor reduces the accumulation and toxicity of misfolded SOD1 in a mouse model of ALS , 2016, Proceedings of the National Academy of Sciences.
[103] M. Grilli,et al. Every Cloud Has a Silver Lining: Proneurogenic Effects of Aβ Oligomers and HMGB-1 via Activation of the RAGE-NF-κB Axis. , 2016, CNS & neurological disorders drug targets.
[104] M. Anderova,et al. Glial Cells - The Key Elements of Alzheimer´s Disease. , 2016, Current Alzheimer research.
[105] K. Blennow,et al. Amyloid precursor protein expression and processing are differentially regulated during cortical neuron differentiation , 2016, Scientific Reports.
[106] D. Brites,et al. Neuroinflammation and Depression: Microglia Activation, Extracellular Microvesicles and microRNA Dysregulation , 2015, Front. Cell. Neurosci..
[107] P. Jendelová,et al. Alzheimer’s Disease: Mechanism and Approach to Cell Therapy , 2015, International journal of molecular sciences.
[108] Andreas U. Monsch,et al. The 12 Years Preceding Mild Cognitive Impairment Due to Alzheimer’s Disease: The Temporal Emergence of Cognitive Decline , 2015, Journal of Alzheimer's disease : JAD.
[109] R. Bucala,et al. Deficiency of macrophage migration inhibitory factor attenuates tau hyperphosphorylation in mouse models of Alzheimer’s disease , 2015, Journal of Neuroinflammation.
[110] E. Diamanti-Kandarakis,et al. Current perspectives on the health risks associated with the consumption of advanced glycation end products: recommendations for dietary management , 2015, Diabetes, metabolic syndrome and obesity : targets and therapy.
[111] Burkhard Becher,et al. Immune attack: the role of inflammation in Alzheimer disease , 2015, Nature Reviews Neuroscience.
[112] Anil Kumar,et al. A review on Alzheimer’s disease pathophysiology and its management: an update , 2015, Pharmacological reports : PR.
[113] A. Descoteaux,et al. Macrophage Cytokines: Involvement in Immunity and Infectious Diseases , 2014, Front. Immunol..
[114] I. Bautmans,et al. Effect of advanced glycation end product intake on inflammation and aging: a systematic review. , 2014, Nutrition reviews.
[115] Steffen Jung,et al. Opposing Effects of Membrane-Anchored CX3CL1 on Amyloid and Tau Pathologies via the p38 MAPK Pathway , 2014, The Journal of Neuroscience.
[116] Teng Jiang,et al. Microglia in Alzheimer's Disease , 2014, BioMed research international.
[117] S. Gauthier,et al. Patterns of Cognitive Decline Prior to Dementia in Persons with Mild Cognitive Impairment , 2014, Alzheimer's & Dementia.
[118] A. Biswas,et al. Raised serum proinflammatory cytokines in Alzheimer's disease with depression. , 2014, Aging and disease.
[119] F. Terro,et al. Involvement of interleukin-1β in the autophagic process of microglia: relevance to Alzheimer’s disease , 2013, Journal of Neuroinflammation.
[120] F. Espíndola,et al. Myosins Are Differentially Expressed under Oxidative Stress in Chronic Streptozotocin-Induced Diabetic Rat Brains , 2013, ISRN neuroscience.
[121] M. Philipp,et al. Cytokines and Chemokines at the Crossroads of Neuroinflammation, Neurodegeneration, and Neuropathic Pain , 2013, Mediators of inflammation.
[122] P. Saharinen,et al. Angiopoietin signaling in the vasculature. , 2013, Experimental cell research.
[123] Li Liu,et al. Palmitate-activated astrocytes via serine palmitoyltransferase increase BACE1 in primary neurons by sphingomyelinases , 2013, Neurobiology of Aging.
[124] J. Morillas-Ruiz,et al. A Review: Inflammatory Process in Alzheimer's Disease, Role of Cytokines , 2012, TheScientificWorldJournal.
[125] F. LaFerla,et al. Blocking IL-1 Signaling Rescues Cognition, Attenuates Tau Pathology, and Restores Neuronal β-Catenin Pathway Function in an Alzheimer’s Disease Model , 2011, The Journal of Immunology.
[126] Ping Wang,et al. VEGF-induced angiogenesis ameliorates the memory impairment in APP transgenic mouse model of Alzheimer's disease. , 2011, Biochemical and biophysical research communications.
[127] Alberto Pupi,et al. PET/CT in diagnosis of dementia , 2011, Annals of the New York Academy of Sciences.
[128] M. Mullan,et al. Depletion of CXCR2 inhibits γ-secretase activity and amyloid-β production in a murine model of Alzheimer's disease. , 2011, Cytokine.
[129] L. Lue,et al. RAGE‐dependent signaling in microglia contributes to neuroinflammation, Aβ accumulation, and impaired learning/memory in a mouse model of Alzheimer's disease , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[130] F. Jessen,et al. The Role of Macrophage Migration Inhibitory Factor in Alzheimer’s Disease , 2010, Molecular medicine.
[131] L. Schultz,et al. Intraventricular infusion of hyperosmolar dextran induces hydrocephalus: a novel animal model of hydrocephalus , 2009, Cerebrospinal Fluid Research.
[132] A. Clayton,et al. The blood brain barrier and the role of cytokines in neuropsychiatry. , 2009, Psychiatry (Edgmont (Pa. : Township)).
[133] Jae Won Chung,et al. Impairment of Instrumental Activities of Daily Living in Patients with Mild Cognitive Impairment , 2009, Psychiatry investigation.
[134] M. Kivipelto,et al. Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention , 2009, Dialogues in clinical neuroscience.
[135] F. Jessen,et al. Macrophage migration inhibitory factor in mild cognitive impairment and Alzheimer's disease. , 2009, Journal of psychiatric research.
[136] D. Geschwind,et al. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease , 2009, Nature Medicine.
[137] N. Durany,et al. Oxidative stress in Alzheimer disease , 2009, Cell adhesion & migration.
[138] C. Lemere,et al. Complement C3 Deficiency Leads to Accelerated Amyloid β Plaque Deposition and Neurodegeneration and Modulation of the Microglia/Macrophage Phenotype in Amyloid Precursor Protein Transgenic Mice , 2008, The Journal of Neuroscience.
[139] S. Kitazume,et al. Interleukin‐1β up‐regulates TACE to enhance α‐cleavage of APP in neurons: resulting decrease in Aβ production , 2008 .
[140] L. Buée,et al. Neurotrophic factors in Alzheimer’s disease: role of axonal transport , 2008, Genes, brain, and behavior.
[141] H. Neumann,et al. Neuronal ‘On’ and ‘Off’ signals control microglia , 2007, Trends in Neurosciences.
[142] C. Masters,et al. Mitochondrial Oxidative Stress Causes Hyperphosphorylation of Tau , 2007, PloS one.
[143] W. Pan,et al. Cytokines Interact with the Blood‐Brain Barrier , 2007 .
[144] R. Dantzer,et al. Named Series: Twenty Years of Brain, Behavior, and Immunity Twenty years of research on cytokine-induced sickness behavior , 2007 .
[145] P. Lucassen,et al. Increased proliferation reflects glial and vascular-associated changes, but not neurogenesis in the presenile Alzheimer hippocampus , 2006, Neurobiology of Disease.
[146] R. N. Saha,et al. Signals for the induction of nitric oxide synthase in astrocytes , 2006, Neurochemistry International.
[147] S. Bandyopadhyay,et al. Interleukin‐1α stimulates non‐amyloidogenic pathway by α‐secretase (ADAM‐10 and ADAM‐17) cleavage of APP in human astrocytic cells involving p38 MAP kinase , 2006 .
[148] Hirohisa Tajima,et al. Neuronal cell death in Alzheimer's disease and a neuroprotective factor, humanin. , 2006, Current neuropharmacology.
[149] S. Barger,et al. Journal of Neuroinflammation Interleukin-1 Mediates Alzheimer and Lewy Body Pathologies , 2022 .
[150] S. Donnini,et al. FGF-2 overexpression opposes the beta amyloid toxic injuries to the vascular endothelium , 2006, Cell Death and Differentiation.
[151] K. Maiese,et al. Erythropoietin Requires NF-κB and its Nuclear Translocation to Prevent Early and Late Apoptotic Neuronal Injury During β-Amyloid Toxicity , 2005 .
[152] M. Schultzberg,et al. Soluble interleukin-1 receptor type II, IL-18 and caspase-1 in mild cognitive impairment and severe Alzheimer's disease , 2005, Neurochemistry International.
[153] V. Mathura,et al. Inflammatory cytokine levels correlate with amyloid load in transgenic mouse models of Alzheimer's disease , 2005, Journal of Neuroinflammation.
[154] S. Roßner,et al. Alzheimer's disease β‐secretase BACE1 is not a neuron‐specific enzyme , 2005 .
[155] K. Fuxe,et al. Nicotine-induced FGF-2 mRNA in rat brain is preserved during aging , 2004, Neurobiology of Aging.
[156] J. Thyberg,et al. Comparative Evaluation of FGF-2–, VEGF-A–, and VEGF-C–Induced Angiogenesis, Lymphangiogenesis, Vascular Fenestrations, and Permeability , 2004, Circulation research.
[157] C. Dinarello,et al. The precursor form of IL-1alpha is an intracrine proinflammatory activator of transcription. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[158] Lin Xie,et al. Increased hippocampal neurogenesis in Alzheimer's disease , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[159] T. Nabeshima,et al. Brain-derived neurotrophic factor/TrkB signaling in memory processes. , 2003, Journal of pharmacological sciences.
[160] T. Wyss-Coray,et al. Adult mouse astrocytes degrade amyloid-β in vitro and in situ , 2003, Nature Medicine.
[161] J. Foidart,et al. Macrophage migration inhibitory factor (MIF) expression in human glioblastomas correlates with vascular endothelial growth factor (VEGF) expression , 2002, Neuropathology and applied neurobiology.
[162] C. Winter,et al. A microdialysis method for the recovery of IL-1β, IL-6 and nerve growth factor from human brain in vivo , 2002, Journal of Neuroscience Methods.
[163] M Chopp,et al. Angiopoietin-1 reduces cerebral blood vessel leakage and ischemic lesion volume after focal cerebral embolic ischemia in mice , 2002, Neuroscience.
[164] John D Lambris,et al. Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[165] Claudio Soto,et al. Reduction of amyloid load and cerebral damage in transgenic mouse model of Alzheimer's disease by treatment with a β‐sheet breaker peptide , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[166] A. Tenner. Complement in Alzheimer’s disease: opportunities for modulating protective and pathogenic events , 2001, Neurobiology of Aging.
[167] R. Nitsch,et al. Formation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Aβ42 Fibrils , 2001, Science.
[168] I. Zachary. Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor. , 2001, American journal of physiology. Cell physiology.
[169] C. Hock,et al. Alterations in Trk A, Trk B and Trk C Receptor Immunoreactivities in Parietal Cortex and Cerebellum in Alzheimer’s Disease , 2000, European Neurology.
[170] G. Siegel,et al. Neurotrophic factors in Alzheimer’s and Parkinson’s disease brain , 2000, Brain Research Reviews.
[171] R Brookmeyer,et al. Age-specific incidence rates of Alzheimer’s disease , 2000, Neurology.
[172] C. Plata-salamán,et al. Inflammation and Alzheimer’s disease , 2000, Neurobiology of Aging.
[173] L. Mucke,et al. Alzheimer's Disease‐like Cerebrovascular Pathology in Transforming Growth Factor‐β1 Transgenic Mice and Functional Metabolic Correlates , 2000, Annals of the New York Academy of Sciences.
[174] J. LaManna,et al. Vascular endothelial growth factor in Alzheimer's disease and experimental cerebral ischemia. , 1998, Brain research. Molecular brain research.
[175] Y. Chong. Effect of a carboxy-terminal fragment of the Alzheimer's amyloid precursor protein on expression of proinflammatory cytokines in rat glial cells. , 1997, Life sciences.
[176] A. Roberts,et al. TGF-β: A Critical Modulator of Immune Cell Function☆ , 1997 .
[177] Yong Ming Li,et al. Enhanced binding of advanced glycation endproducts (AGE) by the ApoE4 isoform links the mechanism of plaque deposition in Alzheimer's disease , 1997, Neuroscience Letters.
[178] S. Skaper,et al. Nerve growth factor: from neurotrophin to neurokine , 1996, Trends in Neurosciences.
[179] C. Brosnan,et al. Expression of type II nitric oxide synthase in primary human astrocytes and microglia: role of IL-1beta and IL-1 receptor antagonist. , 1996, Journal of immunology.
[180] Patrick L. McGeer,et al. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease , 1996, Neurology.
[181] C. Ibáñez,et al. Synergistic Trophic Actions on Rat Basal Forebrain Neurons Revealed by a Synthetic NGF/BDNF Chimaeric Molecule , 1995, The European journal of neuroscience.
[182] B. Yankner,et al. β-Amyloid fibrils induce tau phosphorylation and loss of microtubule binding , 1995, Neuron.
[183] W. Tourtellotte,et al. Transforming growth factor beta in Alzheimer's disease , 1994, Clinical and diagnostic laboratory immunology.
[184] W. Banks,et al. Murine tumor necrosis factor alpha is transported from blood to brain in the mouse , 1993, Journal of Neuroimmunology.
[185] R. Levy,et al. On certain peculiar diseases of old age , 1991, History of psychiatry.
[186] T. Isbir,et al. Potential Protective Role of SDF-1 and CXCR4 Gene Variants in the Development of Dementia. , 2020, Psychiatria Danubina.
[187] Đ. Miljković,et al. MIF and insulin: Lifetime companions from common genesis to common pathogenesis. , 2019, Cytokine.
[188] D. Muresanu,et al. Severity-Related Increase and Cognitive Correlates of Serum VEGF Levels in Alzheimer's Disease ApoE4 Carriers. , 2018, Journal of Alzheimer's disease : JAD.
[189] Harald Hampel,et al. Revisiting the Cholinergic Hypothesis in Alzheimer’s Disease: Emerging Evidence from Translational and Clinical Research , 2018, The Journal of Prevention of Alzheimer's Disease.
[190] S. Joshi,et al. Alzheimer’s Disease:Intracellular Beta Amyloid Completes the Irreversible Pathway from Spirochetes to Biofilms to Beta Amyloid to Hyperphosphorylated Tau Protein , 2018 .
[191] S. Sattler. The Role of the Immune System Beyond the Fight Against Infection. , 2017, Advances in experimental medicine and biology.
[192] H. Wagner,et al. Suche nach Risikogenen bei der Alzheimer-Erkrankung , 2017, Der Nervenarzt.
[193] C. Laske,et al. Dysregulation of neurotrophic and haematopoietic growth factors in Alzheimer's disease: from pathophysiology to novel treatment strategies. , 2014, Current Alzheimer research.
[194] D. Selkoe. Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.
[195] M. Murphy,et al. Alzheimer's disease and the amyloid-beta peptide. , 2010, Journal of Alzheimer's disease : JAD.
[196] C. Laske,et al. Decreased plasma levels of granulocyte-colony stimulating factor (G-CSF) in patients with early Alzheimer's disease. , 2009, Journal of Alzheimer's disease : JAD.
[197] W. Oertel,et al. Immunization as treatment for Parkinson's disease. , 2009, Journal of neural transmission. Supplementum.
[198] C. Laske,et al. Decreased plasma and cerebrospinal fluid levels of stem cell factor in patients with early Alzheimer's disease. , 2008, Journal of Alzheimer's disease : JAD.
[199] S. Kitazume,et al. Interleukin-1 beta up-regulates TACE to enhance alpha-cleavage of APP in neurons: resulting decrease in Abeta production. , 2008, Journal of neurochemistry.
[200] A. Volterra,et al. Glutamate release from astrocytes in physiological conditions and in neurodegenerative disorders characterized by neuroinflammation. , 2007, International review of neurobiology.
[201] S. Bandyopadhyay,et al. Interleukin-1alpha stimulates non-amyloidogenic pathway by alpha-secretase (ADAM-10 and ADAM-17) cleavage of APP in human astrocytic cells involving p38 MAP kinase. , 2006, Journal of neuroscience research.
[202] Robert S Negrin,et al. Hematopoietic stem and progenitor cells: clinical and preclinical regeneration of the hematolymphoid system. , 2005, Annual review of medicine.
[203] K. Maiese,et al. Erythropoietin requires NF-kappaB and its nuclear translocation to prevent early and late apoptotic neuronal injury during beta-amyloid toxicity. , 2005, Current neurovascular research.
[204] T. Wyss-Coray,et al. Adult mouse astrocytes degrade amyloid-beta in vitro and in situ. , 2003, Nature medicine.
[205] A. Roberts,et al. TGF-beta: a critical modulator of immune cell function. , 1997, Clinical immunology and immunopathology.
[206] M. Maes. Α Review on the Acute Phase Response in Major Depression , 1993, Reviews in the neurosciences.
[207] R. Coffman,et al. Lymphokine control of in vivo immunoglobulin isotype selection. , 1990, Annual review of immunology.